Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 1;18(1):360.
doi: 10.1186/s13063-017-2099-9.

Barriers to the conduct of randomised clinical trials within all disease areas

Affiliations
Review

Barriers to the conduct of randomised clinical trials within all disease areas

Snezana Djurisic et al. Trials. .

Abstract

Background: Randomised clinical trials are key to advancing medical knowledge and to enhancing patient care, but major barriers to their conduct exist. The present paper presents some of these barriers.

Methods: We performed systematic literature searches and internal European Clinical Research Infrastructure Network (ECRIN) communications during face-to-face meetings and telephone conferences from 2013 to 2017 within the context of the ECRIN Integrating Activity (ECRIN-IA) project.

Results: The following barriers to randomised clinical trials were identified: inadequate knowledge of clinical research and trial methodology; lack of funding; excessive monitoring; restrictive privacy law and lack of transparency; complex regulatory requirements; and inadequate infrastructures. There is a need for more pragmatic randomised clinical trials conducted with low risks of systematic and random errors, and multinational cooperation is essential.

Conclusions: The present paper presents major barriers to randomised clinical trials. It also underlines the value of using a pan-European-distributed infrastructure to help investigators overcome barriers for multi-country trials in any disease area.

Keywords: Barriers; Bottlenecks; Challenges; Evidence based clinical practice; Evidence based medicine; Hindrances; Randomised clinical trials.

PubMed Disclaimer

Conflict of interest statement

Authors’ information

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors have no competing interests to declare apart from their involvement in clinical trials as well as in ECRIN.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2009 flow diagram, depicting the process for selection of relevant literature

References

    1. National Institute of Health . NIH inventory of clinical trials: fiscal year 1979, vol. I. Bethesda: Division of Research Grants, Research Analysis and Evaluation Branch; 1979.
    1. DeMets DL. Clinical trials in the new millennium. Stat Med. 2002;21(19):2779–87. doi: 10.1002/sim.1281. - DOI - PubMed
    1. Jakobsen JC, Gluud C. The necessity of randomized clinical trials. Br J Med Res. 2013;3(4):i453–1468.
    1. Garattini S, Jakobsen JC, Wetterslev J, Bertele V, Banzi R, Rath A, et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. Eur J Intern Med. 2016;32:13–21. doi: 10.1016/j.ejim.2016.03.020. - DOI - PubMed
    1. Duley L, Antman K, Arena J, Avezum A, Blumenthal M, Bosch J, et al. Specific barriers to the conduct of randomized trials. Clin Trials. 2008;5(1):40–8. doi: 10.1177/1740774507087704. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources